Opko Health Inc (OPK) concluded trading on Thursday at a closing price of $1.33, with 4.21 million shares of worth about $5.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.29% during that period and on May 15, 2025 the price saw a gain of about 5.56%. Currently the company’s common shares owned by public are about 671.61M shares, out of which, 356.63M shares are available for trading.
Stock saw a price change of 5.56% in past 5 days and over the past one month there was a price change of -7.64%. Year-to-date (YTD), OPK shares are showing a performance of -9.52% which increased to 5.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.19 but also hit the highest price of $2.04 during that period. The average intraday trading volume for Opko Health Inc shares is 5.28 million. The stock is currently trading -1.57% below its 20-day simple moving average (SMA20), while that difference is down -13.88% for SMA50 and it goes to -13.95% lower than SMA200.
Opko Health Inc (NASDAQ: OPK) currently have 671.61M outstanding shares and institutions hold larger chunk of about 26.85% of that.
The stock has a current market capitalization of $1.05B and its 3Y-monthly beta is at 1.37. It has posted earnings per share of -$0.08 in the same period. It has Quick Ratio of 2.28 while making debt-to-equity ratio of 0.37. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OPK, volatility over the week remained 4.97% while standing at 4.92% over the month.
Stock’s fiscal year EPS is expected to drop by -326.79% while it is estimated to increase by 40.17% in next year. EPS is likely to shrink at an annualized rate of -11.20% for next 5-years, compared to annual growth of 32.04% made by the stock over the past 5-years.
Coverage by Barrington Research stated Opko Health Inc (OPK) stock as an Outperform in their note to investors on June 29, 2023, suggesting a price target of $2 for the stock. Stock get a Buy rating from Ladenburg Thalmann on June 21, 2021.
